Monotherapy for treating type 2 diabetes (NICE TA390)
NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
Canagliflozin, dapagliflozin and empagliflozin as monotherapies are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if:
a dipeptidyl peptidase‑4 (DPP‑4) inhibitor would otherwise be prescribed and
a sulfonylurea or pioglitazone is not appropriate.
The LSCMMG recommends dapagliflozin as a 1st line ““gliflozin””.
Reason for decision:
Suitable for initiation in primary care